Filing Details

Accession Number:
0000899243-23-002674
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-25 18:04:31
Reporting Period:
2023-01-23
Accepted Time:
2023-01-25 18:04:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1590750 Viridian Therapeutics Inc. VRDN Services-Medical Laboratories (8071) 471187261
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1883986 Lara Meisner C/O Viridian Therapeutics, Inc.
221 Crescent Street, Suite 401
Waltham MA 02453
General Counsel And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-23 4,971 $23.03 4,971 No 4 M Direct
Common Stock Acquisiton 2023-01-23 1,872 $14.00 6,843 No 4 M Direct
Common Stock Disposition 2023-01-23 6,843 $35.66 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-01-23 4,971 $0.00 4,971 $23.03
Common Stock Stock Option (Right to Buy) Disposition 2023-01-23 1,872 $0.00 1,872 $14.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
39,750 2031-01-18 No 4 M Direct
20,003 2031-09-22 No 4 M Direct
Footnotes
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $35.22 to $36.06. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
  3. The option vested 25% on September 22, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.